# Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

> **NCT00425555** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 139 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT00425555
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425555, "Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00425555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*